Substrate specificity of the galactokinase from the human gut symbiont Akkermansia muciniphila ATCC BAA-835,Enzyme and Microbial Technology

当前位置： X-MOL 学术 › Enzyme Microb. Technol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Substrate specificity of the galactokinase from the human gut symbiont Akkermansia muciniphila ATCC BAA-835
Enzyme and Microbial Technology ( IF 3.4 ) Pub Date : 2020-09-01 , DOI: 10.1016/j.enzmictec.2020.109568
Xunlian Zhang ₁ , Weihao Sheng ₁ , Kun Li ₁ , Yongheng Rong ₁ , Qizheng Wu ₁ , Qingyun Meng ₁ , Yun Kong ₁ , Min Chen ₁

Affiliation

Galactokinases, which catalyze the phosphorylation of galactose and possible other monosaccharides, can provide an activated sugar donor to synthesize sugar-containing molecules. In this study, a novel galactokinase from human gut symbiont Akkermansia muciniphila ATCC BAA-835 (GalKAmu) was expressed and characterized. GalKAmu displayed broad substrate tolerance, with catalytic activity towards Gal (100 %), GalN (100 %), GalA (20.2 %), Glc (52.5 %), GlcNAc (15.5 %), Xyl (<5%), ManNAc (58 %), ManF (37.4 %) and l-Glc (80 %). Most interestingly, this was the first GalK isoform which can tolerate ManNAc. Thus, our characterization of GalKAmu broadens the substrate selection of galactokinases.

中文翻译：

来自人类肠道共生体 Akkermansia muciniphila ATCC BAA-835 的半乳糖激酶的底物特异性

半乳糖激酶催化半乳糖和可能的其他单糖的磷酸化，可以提供活化的糖供体来合成含糖分子。在这项研究中，表达并表征了一种来自人类肠道共生体 Akkermansia muciniphila ATCC BAA-835 (GalKAmu) 的新型半乳糖激酶。GalKAmu 显示出广泛的底物耐受性，对 Gal (100 %)、GalN (100 %)、GalA (20.2 %)、Glc (52.5 %)、GlcNAc (15.5 %)、Xyl (<5%)、ManNAc (58) 具有催化活性%)、ManF (37.4%) 和 l-Glc (80%)。最有趣的是，这是第一个可以耐受 ManNAc 的 GalK 异构体。因此，我们对 GalKAmu 的表征拓宽了半乳糖激酶的底物选择。

更新日期：2020-09-01

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11